Compare HBIO & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | TELA |
|---|---|---|
| Founded | 1901 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 31.4M |
| IPO Year | 2000 | 2019 |
| Metric | HBIO | TELA |
|---|---|---|
| Price | $9.50 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $11.50 | $1.80 |
| AVG Volume (30 Days) | 26.4K | ★ 134.4K |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | $80,275,000.00 |
| Revenue This Year | $4.09 | N/A |
| Revenue Next Year | $5.22 | $8.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.40 | $0.50 |
| 52 Week High | $10.20 | $1.50 |
| Indicator | HBIO | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 41.39 |
| Support Level | $8.01 | $0.78 |
| Resistance Level | N/A | $0.97 |
| Average True Range (ATR) | 0.51 | 0.13 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 66.51 | 32.57 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.